Impact of Adjusted Creatinine Clearance on Carboplatin Dosing in Endometrial Cancer: A Retrospective Study

Abstract

Carboplatin (CBDCA) dosing is commonly determined using the Calvert formula, with creatinine clearance (Ccr) estimated by the Cockcroft-Gault formula. In Japan, where serum creatinine (sCr) is usually measured enzymatically, unadjusted Ccr may overestimate glomerular filtration rate and lead to CBDCA overdosing. We retrospectively compared treatment exposure, hematologic toxicity, and exploratory oncologic outcomes in patients with endometrial cancer who received postoperative paclitaxel plus CBDCA therapy. Patients were grouped according to whether CBDCA dosing was based on the conventional Cockcroft-Gault formula (CG group) or on adjusted Ccr calculated by adding 0.2 mg/dL to sCr (adjusted group). The incidence of Grade ≥3 neutropenia was significantly lower in the adjusted group than in the CG group. The 5-year progression-free survival (PFS) rate was numerically lower in the adjusted group than in the CG group, although no statistically significant difference was observed between the groups. Because the number of PFS events was limited, the effect of adjusted Ccr-based dosing on oncologic outcomes remains uncertain. These findings suggest that adjusted Ccr-based dosing may reduce hematologic toxicity in routine clinical practice. However, given the limited number of PFS events and the wide uncertainty in survival estimates, further studies are needed to clarify its impact on oncologic outcomes.

Nonlinear association between cockcroft-gault creatinine clearance and all-cause mortality in critically ill cerebrovascular disease patients: a retrospective cohort study
Hui Wang
Scientific Reports1 Jul 2026Peer-reviewedCC BYFull textGeneral medicineDOAJ
Creatinine Clearance, Ceftazidime-Avibactam Exposure, and Clinical Outcomes in a Real-World TDM Cohort: A Retrospective Observational Study.
Bo Yang, Jianbiao Meng, Bei Zheng +6
Drug design, development and therapy17 Oct 2026Peer-reviewedCC BY-NCFull textPharmacology & toxicologyEurope PMC
Eicosapentaenoic acid exhibits antitumor effects and synergistically enhances carboplatin sensitivity in endometrial cancer
Haomeng Zhang, Weimin Kong, Shuning Chen +8
Frontiers in Pharmacology21 Oct 2026Peer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossrefPMC
Echinococcus granulosus Genotype and Surgical Outcomes After Cystic Echinococcosis Surgery: A Propensity-Score-Adjusted Retrospective Pilot Cohort Study
Mehmet Kadir Bartın, Müge Kara
Tropical medicine and infectious disease29 Sep 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC
Association between delayed thromboprophylaxis and the incidence of deep vein thrombosis in patients with pelvic trauma: a retrospective cohort adjusted for severity at a level I trauma center
Jihad Manaf El Sayed, Guilherme Marum Olmedo, Adilia Maria Pires Sciarra +2
Jornal vascular brasileiro19 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMC

Cite

BibTeX RIS

BibTeX

@article{katayama2026impact,
  title = {{Impact of Adjusted Creatinine Clearance on Carboplatin Dosing in Endometrial Cancer: A Retrospective Study}},
  author = {Kentaro Katayama and Makio Imamura and Takashi Uehara},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2026},
  month = aug,
  doi = {10.1248/bpb.b26-00201},
  url = {https://www.jstage.jst.go.jp/article/bpb/49/8/49_b26-00201/_article},
  note = {CC BY-NC},
}

RIS

TY  - JOUR
TI  - Impact of Adjusted Creatinine Clearance on Carboplatin Dosing in Endometrial Cancer: A Retrospective Study
AU  - Kentaro Katayama
AU  - Makio Imamura
AU  - Takashi Uehara
PY  - 2026
DA  - 2026/08/25
JO  - Biological and Pharmaceutical Bulletin
DO  - 10.1248/bpb.b26-00201
UR  - https://www.jstage.jst.go.jp/article/bpb/49/8/49_b26-00201/_article
AB  - Carboplatin (CBDCA) dosing is commonly determined using the Calvert formula, with creatinine clearance (Ccr) estimated by the Cockcroft-Gault formula. In Japan, where serum creatinine (sCr) is usually measured enzymatically, unadjusted Ccr may overestimate glomerular filtration rate and lead to CBDCA overdosing. We retrospectively compared treatment exposure, hematologic toxicity, and exploratory oncologic outcomes in patients with endometrial cancer who received postoperative paclitaxel plus CBDCA therapy. Patients were grouped according to whether CBDCA dosing was based on the conventional Cockcroft-Gault formula (CG group) or on adjusted Ccr calculated by adding 0.2 mg/dL to sCr (adjusted group). The incidence of Grade ≥3 neutropenia was significantly lower in the adjusted group than in the CG group. The 5-year progression-free survival (PFS) rate was numerically lower in the adjusted group than in the CG group, although no statistically significant difference was observed between the groups. Because the number of PFS events was limited, the effect of adjusted Ccr-based dosing on oncologic outcomes remains uncertain. These findings suggest that adjusted Ccr-based dosing may reduce hematologic toxicity in routine clinical practice. However, given the limited number of PFS events and the wide uncertainty in survival estimates, further studies are needed to clarify its impact on oncologic outcomes.
SN  - 1347-5215
SN  - 0918-6158
ER  -

Abstract

Related

Cite